1
Clinical Trials associated with Autologous CSR T(Marino Biotechnology) / Unknown statusPhase 1IIT A Safety and Efficacy Study of Chimeric Switch Receptor Modified T Cells in Patients With Recurrent or Metastatic Malignant Tumors
A Chimeric Switch Receptor, which was constructed by fusing the PD1 extracellular ligand binding domain to the CD28 intracellular costimulatory domain, was designed to target PD-L 1 positive tumors . In this single-arm, open-label, one center, dose escalation clinical study, the main purpose is to determine the safety and efficacy of infusion of autologous Chimeric Switch Receptor modified T cells (CSR T) in adult patients with PD-L1 positive, recurrent or metastatic malignant tumors.
100 Clinical Results associated with Autologous CSR T(Marino Biotechnology)
100 Translational Medicine associated with Autologous CSR T(Marino Biotechnology)
100 Patents (Medical) associated with Autologous CSR T(Marino Biotechnology)
100 Deals associated with Autologous CSR T(Marino Biotechnology)